Linagliptin/Metformin ER FDC

DRUG2 trials

Sponsors

Boehringer Ingelheim

Conditions

Healthy

Phase 1

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (5mg/1000mg) Extended Release in Healthy Subjects

CompletedNCT02084082

Boehringer IngelheimHealthy

Start: 2014-04-30End: 2014-07-31Updated: 2016-08-04

Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

CompletedNCT02121509

Boehringer IngelheimHealthy

Start: 2014-05-31End: 2014-07-31Updated: 2016-08-04